Antibody libraries

1. A method of making a library comprising synthetic polynucleotides that encode an antibody heavy chain containing at least about 10 4 unique antibody CDRH3 amino acid sequences, wherein each of the polynucleotides encoding the at least about 10 4 unique antibody CDRH3 amino acid sequences has an antibody CDRH3 amino acid sequence represented by the following formula: [TN1]-[DH]-[N2]-[H3-JH], the method comprising:

(a) providing a theoretical segment pool containing TN1, DH, N2, and H3-JH segments, wherein the H3-JH segments are provided according to the following steps:

(i) obtaining a set of polynucleotide sequences of human IGHJ genes and alleles;

(ii) progressively deleting at least one nucleotide base from the 5′ end of the polynucleotide sequences of (i);

(iii) systematically adding at least one nucleotide base to the 5′ end of the polynucleotide sequences from (ii); and

(iv) translating the modified polynucleotide sequences of (iii) and selecting unique amino acid sequences to thereby provide the H3-JH theoretical segment pool;

(b) providing a reference set of preimmune CDRH3 sequences having sequence diversities and length diversities similar to naturally occurring human antibody sequences before these sequences have undergone negative selection and/or hypermutation;

(c) utilizing combinations of the TN1, DH, N2, and H3-JH segments contained in the theoretical segment pool of (a) to identify the closest match(es) to each CDRH3 sequence in the reference set of (b);

(d) selecting segments from the closest match(es) identified in step (c) for inclusion in a library comprising synthetic polynucleotides that encode an antibody heavy chain; and

(e) synthesizing the synthetic polynucleotides that encode an antibody heavy chain;

wherein the diversity of the polynucleotides encoding the at least about 10 4 unique antibody CDRH3 amino acid sequences is created by polynucleotides having CDRH3 sequences that are different from the CDRH3 sequences of other polynucleotides; and

wherein the antibody heavy chain is a variable domain with framework (FRM) and complementary determining regions (CDRs) comprising FRMH1-CDRH1-FRMH2-CDRH2-FRMH3-CDRH3-FRM4.

2. The method of claim 1 , wherein step (a)(ii) comprises progressive single base deletions.

3. The method of claim 1 , wherein step (a)(ii) comprises progressively deleting at least one nucleotide base until only the sequence corresponding to FRM4 remains.

4. The method of claim 1 , wherein step (a)(ii) comprises progressively deleting at least one nucleotide base until the polynucleotide sequence encodes only a single amino acid residue in the H3-JH segment.

5. The method of claim 1 , wherein step (a)(iii) comprises systematically adding 1 or 2 nucleotide bases to the 5′ end of the polynucleotide sequences from (ii).

6. The method of claim 1 , wherein the unique sequences selected in step (a)(iv) do not comprise FRM4.

7. The method of claim 1 , wherein the segments selected for inclusion in the synthetic library are selected according to their segment usage weight in the reference set of CDRH3 sequences.

8. The method of claim 1 , wherein the segments selected for inclusion in the synthetic library are selected according to one or more physicochemical properties.

9. The method of claim 1 , further comprising selecting additional TN1 and N2 segments occurring in the reference set but not in the theoretical segment pool.

10. The method of claim 1 , wherein stop codons are reduced or eliminated from the library.

11. The method of claim 1 , wherein the unpaired Cys residues, N-linked glycosylation motifs, and deamidation motifs are reduced or eliminated in the translation products of the library.

12. The method of claim 1 , wherein the H3-JH segments are about 0 to about 10 amino acids in length.

13. The method of claim 1 , wherein the theoretical segment pool contains TN1 segments corresponding to any of the TN1 polypeptides of Tables 10 and 18-26, or a polypeptide produced by translation of any of the TN1-encoding polynucleotides of Tables 25-26.

14. The method of claim 1 , wherein the theoretical segment pool contains DH segments corresponding to any of the DH polypeptides of Tables 11, 17-25 and 28, or a polypeptide produced by translation of any of the DH-encoding polynucleotides of Tables 16, 25, and 27.

15. The method of claim 1 , wherein the theoretical segment pool contains N2 segments corresponding to any of the N2 polypeptides of Tables 12, 18-25, and 30, or a polypeptide produced by translation of any of the N2-encoding polynucleotides of Tables 25 and 29.

16. The method of claim 1 , wherein the theoretical segment pool contains H3-JH segments corresponding to any of the H3-JH polypeptides of Tables 13, 15, 18-25, and 32, or a polypeptide produced by translation of any of the H3-JH encoding polynucleotides of Tables 14, 25, and 31.

17. The method of claim 1 , wherein the unique sequences of (iv) do not have stop codons, unpaired Cys residues, deamidation motifs, or Asn in the last or next to last position that can lead to N-linked glycosylation motifs.

18. The method of claim 1 , wherein step (a)(iii) comprises systematically adding a NN doublet or NNN triplet at the 5′ end of the sequence.